Nasdaq:AGIO

– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) —

– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) —

– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) —

– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) —

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET CAMBRIDGE, Mass., Nov.

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism